Skip to main content

Conservative management options for peyronie’s disease

Current Urology Reports volume 6, pages 454–460 (2005)Cite this article

Abstract

Peyronie’s disease is an acquired condition that presents clinically with a palpable induration, a distinct plaque, or a curvature of the erect penis. At times, the erections are painful. Erectile dysfunction (ED) often is associated with Peyronie’s disease. The current era of phosphodiesterase therapy for the treatment of ED seems to have increased the number of patients presenting for treatment of Peyronie’s disease. During the past decade, significant advances have been made in understanding the pathophysiology of the disease, resulting in numerous nonsurgical therapies proposed for the treatment of Peyronie’s disease. These medical treatments can be administered systemically, locally, or intralesionally. Unfortunately, there are few randomized, placebo-controlled trials to evaluate most of these proposed therapies. In evaluating therapies for Peyronie’s disease, it must be remembered that the natural disease history includes spontaneous resolution of pain and even a small improvement in penile curvature in some men. This article reviews the natural history, scientific understanding, and nonsurgical treatment options for the mild to moderate Peyronie’s deformities. Surgical therapy remains the mainstay of treatment for severe and refractory cases of Peyronie’s disease that result in a physical or psychologic dysfunction.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

References and Recommended Reading

  1. Lindsay MB, Schain DM, Grambasch P: The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991, 146:1007–1009.

    PubMed  CAS  Google Scholar 

  2. Braun M, Wassmer G, Klotz T, et al.: Epidemiology of erectile dysfunction: results of ’Cologne Male Survey’. Int J Impot Res 2000, 12:305–311.

    Article  PubMed  CAS  Google Scholar 

  3. Smith BH: Subclinical Peyronie’s disease. Am J Clin Pathol 1969, 52:385–390.

    PubMed  CAS  Google Scholar 

  4. Gelbard MK, Dorey F, James K: The natural history of Peyronie’s disease. J Urol 1990, 128:1376–1379.

    Google Scholar 

  5. Weidner W, Schroeder-Printzen I, Weiske W, et al.: Sexual function in Peyronie’s disease: an analysis of 222 patients without previous local plaque therapy. J Urol 1997, 157:325–328.

    Article  PubMed  CAS  Google Scholar 

  6. Pryor JP: Peyronie’s disease and impotence. Acta Urol Belg 1988, 56:317–321.

    PubMed  CAS  Google Scholar 

  7. Lopez JA, Jarow JP: Penile vascular evaluation of men with Peyronie’s disease. J Urol 1993, 149:53–55.

    PubMed  CAS  Google Scholar 

  8. Furey CA: Peyronie’s disease: a treatment by the local injection of meticortelone and hydrocortisone. J Urol 1957, 55:251–266.

    Google Scholar 

  9. Jarow JP, Lowe FC: Penile trauma: an etiologic factor in Peyronie’s disease and erectile dysfunction. J Urol 1997, 158:1388–1390.

    Article  PubMed  CAS  Google Scholar 

  10. Hinman F Jr: Etiologic factors in Peyronie’s disease. Urol Int 1980, 35:407–413.

    Article  PubMed  Google Scholar 

  11. Chilton CP, Castle WM: Factors associated with the aetiology of Peyronie’s disease. Br J Urol 1982, 54:748–750.

    PubMed  CAS  Google Scholar 

  12. Bystrom J, Rubio C: Induratio penis plastica: clinical features and aetiology. Scand J Urol Nephrol 1976, 10:12–20.

    PubMed  CAS  Google Scholar 

  13. Schiavino D, Sasso F, Nucera E, et al.: Immunologic findings in Peyronie’s disease: a controlled study. Urology 1997, 50:764–768.

    Article  PubMed  CAS  Google Scholar 

  14. Stewart S, Malto M, Sandberg L, et al.: Increased serum levels of anti-elastin antibodies in patients with Peyronie’s disease. J Urol 1994, 152:105–106.

    PubMed  CAS  Google Scholar 

  15. El-Sakka AI, Hassoba HM, Pillarisetty RJ, et al.: Peyronie’s disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997, 158:1391–1394.

    Article  PubMed  CAS  Google Scholar 

  16. Ferrini MG, Vernet D, Magee TR, et al.: Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide 2002, 6:283–294.

    Article  PubMed  CAS  Google Scholar 

  17. Scott WW, Scardino PA: A new concept in the treatment of Peyronie’s disease. South Med J 1948, 41:173–177.

    PubMed  CAS  Google Scholar 

  18. Gelbard MK, Dorey F, James K: The natural history of Peyronie’s disease. J Urol 1990, 128:1376–1379.

    Google Scholar 

  19. Pryor JP, Farrell CF: Controlled clinical trial of vitamin E in Peyronie’s disease. Prog Reprod Bio 1983, 9:41–45. A controlled trial of vitamin E demonstrating that the only benefit of vitamin E was in pain reduction.

    Google Scholar 

  20. Weidner W, Hauck EW, Schnitker J: Peyronie’s Disease Study Group of Andrological Group of German Urologists. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. Eur Urol 2005, 47:530–535.

    Article  PubMed  CAS  Google Scholar 

  21. Ralph DJ, Brooks MD, Bottazzo GF, et al.: The treatment of Peyronie’s disease with tamoxifen. Br J Urol 1992, 70:648–651.

    Article  PubMed  CAS  Google Scholar 

  22. Teloken C, Rhoden EL, Grazziotin TM, et al.: Tamoxifen versus placebo in the treatment of Peyronie’s disease. J Urol 1999, 162:2003–2005. A small randomized trial comparing tamoxifen with placebo.

    Article  PubMed  CAS  Google Scholar 

  23. Biagiotti G, Cavallini G: Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie’s disease: a preliminary report. BJU Int 2001, 88:63–67.

    Article  PubMed  CAS  Google Scholar 

  24. Cavallini G, Biagiotti G, Koverech A, et al.: Oral propionyl-lcarnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie’s disease. BJU Int 2002, 89:895–900.

    Article  PubMed  CAS  Google Scholar 

  25. Akkus E, Carrier S, Rehman J, et al.: Is colchicine effective in Peyronie’s disease? A pilot study. Urology 1994, 44:291–295.

    Article  PubMed  CAS  Google Scholar 

  26. Carson CC: Potassium para-aminobenzoate for the treatment of Peyronie’s disease: Is it effective? Tech Urol 1997, 3:135–139.

    PubMed  CAS  Google Scholar 

  27. Safarinejad MR: Therapeutic effects of colchicine in the management of Peyronie’s disease: a randomized, double-blind, placebo-controlled study. Int J Impot Res 2004, 16:238–243. A succinct placebo-controlled trial.

    Article  PubMed  CAS  Google Scholar 

  28. Winter CC, Khana R: Peyronie’s disease: results with dermojet injection of dexamethasone. J Urol 1975, 114:898–900.

    PubMed  CAS  Google Scholar 

  29. Levine LA, Goldman KE, Greenfield JM: Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol 2002, 168:621–626. A good description of the early experience and technique of the verapamil injection.

    Article  PubMed  CAS  Google Scholar 

  30. Rehman J, Benet A, Melman A: Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term, singleblind study. Urology 1998, 51:620–626.

    Article  PubMed  CAS  Google Scholar 

  31. Teloken C: Objective evaluation of non-surgical approach for Peyronie’s disease. J Urol 1996, 155:633A.

    Google Scholar 

  32. Gelbard MK, James K, Riach P, et al.: Collagenase versus placebo in the treatment of Peyronie’s disease: a doubleblind study. J Urol 1993, 149:56–58.

    PubMed  CAS  Google Scholar 

  33. Ahuja S, Bivalacqua TJ, Case J, et al.: A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie’s disease. J Androl 1999, 20:444–448.

    PubMed  CAS  Google Scholar 

  34. Fitch WP, Easterling WJ: Topical verapamil, trifluoperazine, and magnesium sulfate for Peyronie’s disease. J Urol 2002, 167(suppl):205–205.

    Google Scholar 

  35. Martin DJ, Badwan K, Parker M, Mulhall JP: Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 2002, 168:2483–2485.

    Article  PubMed  CAS  Google Scholar 

  36. Riedl CR, Sternig P, Galle G, et al.: Recombinant human superoxide dismutase for the treatment of Peyronie’s disease: a randomized, placebo-controlled, double-blind, prospective clinical study. Eur Urol 2005 [Epub ahead of print].

  37. Manikandan R, Islam W, Srinivasan V, Evans CM: Evaluation of extracorporeal shock wave therapy in Peyronie’s disease. Urology 2002, 60:795–800.

    Article  PubMed  CAS  Google Scholar 

  38. Hauck EW, Altinkilic BM, Ludwig M, et al.: Extracorporeal shock wave therapy in the treatment of Peyronie’s disease: first results of a case-controlled approach. Eur Urol 2000, 38:663–670. The only case-controlled study available on ESWT.

    Article  PubMed  CAS  Google Scholar 

  39. Hauck EW, Mueller UO, Bschleipfer T, et al.: Extracorporeal shock wave therapy for Peyronie’s disease: exploratory meta-analysis of clinical trials. J Urol 2004, 171:740–745. A summary of all of the ESWT trials and data.

    Article  PubMed  Google Scholar 

  40. Di Stasi SM, Giannantoni A, Stephen RL: A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. J Urol 2004, 171:1605–1608.

    Article  PubMed  CAS  Google Scholar 

  41. Montorsi F, Salonia A, Guazzoni G, et al.: Transdermal electromotive multidrug administration for Peyronie’s disease: preliminary results. J Androl 2000, 21:85–90.

    PubMed  CAS  Google Scholar 

  42. Levine LA, Estrada CR, Shou W, et al.: Tunica albuginea tissue analysis following electromotive drug administration (EMDA). J Urol 2003, 169:1775–1778.

    Article  PubMed  CAS  Google Scholar 

  43. Perugia G, Liberti M, Vicini P, Colistro F: Role of hyperthermia in the treatment of Peyronie’s disease: a preliminary study. Int J Hyperthermia 2005, 21:367–374.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, County of Los Angeles Harbor, UCLA Medical Center, 1000 West Carson Street, 90509, Torrence, CA, USA

    Jacob Rajfer MD

Authors
  1. Gregory S. Jack MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nestor Gonzalez-Cadavid PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jacob Rajfer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Jack, G.S., Gonzalez-Cadavid, N. & Rajfer, J. Conservative management options for peyronie’s disease. Curr Urol Rep 6, 454–460 (2005). https://doi.org/10.1007/s11934-005-0041-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-005-0041-2

Keywords

  • Tamoxifen
  • Verapamil
  • Erectile Dysfunction
  • Extracorporeal Shock Wave Therapy
  • Tunica Albuginea